{"id":"sb8","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hypertension"},{"rate":"15-25","effect":"Proteinuria"},{"rate":"5-15","effect":"Bleeding"},{"rate":"5-10","effect":"Thromboembolic events"},{"rate":"0.5-2","effect":"Gastrointestinal perforation"},{"rate":"5-10","effect":"Wound healing complications"}]},"_chembl":{"chemblId":"CHEMBL5428017","moleculeType":null,"molecularWeight":"549.68"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SB8 is a monoclonal antibody that binds to and neutralizes VEGF, a key signaling molecule that promotes the formation of new blood vessels. By blocking VEGF, SB8 prevents tumors from developing their own blood supply, thereby inhibiting tumor growth and metastasis. As a bevacizumab biosimilar developed by Samsung Bioepis, it is designed to have comparable efficacy and safety to the reference biologic.","oneSentence":"SB8 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:33:35.571Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Non-squamous non-small cell lung cancer"},{"name":"Metastatic breast cancer"},{"name":"Renal cell carcinoma"}]},"trialDetails":[{"nctId":"NCT02754882","phase":"PHASE3","title":"A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2016-07-05","conditions":"Lung Cancer, Non-small Cell Lung Cancer","enrollment":763},{"nctId":"NCT02453672","phase":"PHASE1","title":"Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2015-04","conditions":"Healthy","enrollment":119}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":59,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SB8 (A proposed bevacizumab biosimilar)"],"phase":"phase_3","status":"active","brandName":"SB8","genericName":"SB8","companyName":"Samsung Bioepis Co., Ltd.","companyId":"samsung-bioepis-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SB8 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells. Used for Metastatic colorectal cancer, Non-squamous non-small cell lung cancer, Metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}